Fig. 1From: Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in ChinaFlow chart of inclusion of the study subjectsBack to article page